Hit by sur­prise set­back, As­traZeneca scram­bles to ex­plain why its two-in-one COPD in­haler was beat­en by GSK ri­val

As­traZeneca was ex­pect­ing a Phase II­Ib tri­al to put its two-in-one COPD in­haler on top of Glax­o­SmithK­line’s ri­val prod­uct. In­stead, it was hit by a trou­bling set­back.

The com­pa­ny re­port­ed that while Bevespi Aeros­phere (gly­copy­rro­ni­um/for­moterol fu­marate) didn’t do worse than GSK’s Anoro (ume­cli­dini­um/vi­lanterol) on peak forced ex­pi­ra­to­ry vol­ume in one sec­ond (FEV1), it didn’t do bet­ter ei­ther. And on trough FEV1, the oth­er co-pri­ma­ry end­point, As­traZeneca’s in­haler per­formed worse.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER